RESULTS The global antihypertensive activity of ARB differs from that observed with amlodipine in the sense that the magnitude of the reduction in the BP values does not essentially depend on the initial BP values nor on the dose used .
When only ARB were considered , the drug used was a determinant for systolic BP reduction , whereas for diastolic BP the influence was on the BP reduction and the duration of the antihypertensive activity .
The dose used had a particular influence on the duration of the antihypertensive activity for both systolic and diastolic BP .
CONCLUSION Among the ARB , the influence is on duration more than on the magnitude of BP reduction .
Dose , therefore , is an important factor in the duration of antihypertensive activity
OBJECTIVE To perform a systematic review of the antihypertensive activity of the angiotensin II AT1 receptor antagonists ( ARB ) .
ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension
The antihypertensive efficacy and tolerability profiles of the selective AT1 receptor antagonists telmisartan and losartan were compared with placebo in a 6-week , multinational , multicentre , r and omised , double-blind , double-dummy , parallel-group study of 223 patients with mild-to-moderate hypertension , defined as clinic diastolic blood pressure ( DBP ) ⩾95 and ⩽114 mm Hg , clinic systolic blood pressure ( SBP ) ⩾140 and ⩽200 mm Hg , and 24-h ambulatory DBP ⩾85 mm Hg . After a 4-week single-blind placebo run-in , eligible patients were r and omised to receive telmisartan 40 mg , telmisartan 80 mg , losartan 50 mg , or placebo . Ambulatory blood pressure monitoring ( ABPM ) after 6 weeks of double-blind therapy showed that all active treatments produced significant ( P < 0.01 ) reductions from baseline in 24-h mean sbp and dbp compared with placebo . during the 18-to-24 h period after dosing , the reductions in sbp/dbp  with telmisartan 40 mg ( 10.7/6.8 mm hg ) and 80 mg ( 12.2/7.1 mm hg ) were each significantly ( P < 0.05 ) greater than those observed for losartan 50 mg ( 6.0/3.7 mm hg ) , and losartan was no better than placebo . also for the 24-h mean blood pressure  , telmisartan 40 mg and 80 mg were significantly ( P < 0.05 ) better than losartan 50 mg . compared with losartan , telmisartan 80 mg produced significantly ( P < 0.05 ) greater reductions in both sbp and dbp during all monitored periods of the 24-h period , while telmisartan 40 mg produced significantly greater reductions in sbp and dbp in the night-time period ( 10.01 pm to 5.59 am ) ( P < 0.05 ) and in dbp in the morning period ( 6.00 am to 11.59 am ) ( P < 0.05 ) . all treatments were comparably well tolerated . telmisartan 40 mg and 80 mg once daily were effective and well tolerated in the treatment of mild-to-moderate hypertension , producing sustained 24-h blood pressure control which compared favourably with losartan
RESULTS The global antihypertensive activity of ARB differs from that observed with amlodipine in the sense that the magnitude of the reduction in the BP values does not essentially depend on the initial BP values nor on the dose used .
When only ARB were considered , the drug used was a determinant for systolic BP reduction , whereas for diastolic BP the influence was on the BP reduction and the duration of the antihypertensive activity .
The dose used had a particular influence on the duration of the antihypertensive activity for both systolic and diastolic BP .
CONCLUSION Among the ARB , the influence is on duration more than on the magnitude of BP reduction .
Dose , therefore , is an important factor in the duration of antihypertensive activity
OBJECTIVE To perform a systematic review of the antihypertensive activity of the angiotensin II AT1 receptor antagonists ( ARB ) .